で公開中です！ 詳しく見る
SYBXのアイコン

Synlogic
SYBX

上場廃止済み

SYBXは2026年1月20日に上場廃止となりました。

ランキングに戻る
 

概要： Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

従業員数： 1

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ニュートラル
GlobeNewsWire
昨年
Synlogic Reports Third Quarter 2024 Financial Results
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update.
Synlogic Reports Third Quarter 2024 Financial Results
ニュートラル
GlobeNewsWire
2 年前
Synlogic Reports Second Quarter 2024 Financial Results
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.
Synlogic Reports Second Quarter 2024 Financial Results
ネガティブ
InvestorPlace
2 年前
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
“Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.
ニュートラル
GlobeNewsWire
2 年前
Synlogic Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.
Synlogic Reports First Quarter 2024 Financial Results
ネガティブ
Zacks Investment Research
2 年前
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
ニュートラル
GlobeNewsWire
2 年前
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
ニュートラル
GlobeNewsWire
2 年前
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
Synlogic Adopts Limited Duration Stockholders Rights Plan
ネガティブ
InvestorPlace
2 年前
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.
ニュートラル
GlobeNewsWire
2 年前
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU).
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
ニュートラル
GlobeNewsWire
2 年前
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています